This exceeds published phase 3 data for semaglutide 2.4mg (14.9% at 68 weeks
Cash-pay compounded GLP-1 programs start around $129/month
Baseline assessment before initiating Mounjaro should include: Renal function tests (estimated glomerular filtration rate) Serum electrolytes including potassium Review of concurrent medications Assessment of cardiovascular status Ongoing monitoring recommendations include: Routine follow-up : For uncomplicated patients without risk factors, electrolyte monitoring can follow standard diabetes care protocols, typically annually or as clinically indicated Enhanced monitoring : Patients with risk factors (renal impairment, concurrent diuretics, elderly) should have electrolytes checked 1-3 months after initiation and following dose escalations, following local protocols Symptomatic monitoring : Any patient experiencing persistent gastrointestinal symptoms, particularly vomiting or diarrhoea lasting more than 48 hours, should have electrolytes assessed Management strategies for patients on Mounjaro include: Dose titration : Following the recommended gradual dose escalation schedule (starting at 2.5 mg weekly for 4 weeks, then increasing to 5 mg, with further increases in 2.5 mg increments to 10-15 mg as needed) helps minimise gastrointestinal adverse effects Non-pharmacological measures : Eating smaller, more frequent meals and maintaining adequate hydration may help reduce gastrointestinal symptoms Symptomatic treatment : If non-pharmacological measures are insufficient, antiemetics may be considered for persistent nausea, though should be used judiciously with consideration of potential QT interval effects and drug interactions Hydration advice : Patients should be counselled to maintain adequate fluid intake, particularly during the initial treatment period If electrolyte disturbances are identified, management should address the underlying cause
These findings apply across diverse populations and are consistent across multiple large-scale trials
